Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
Status:
Completed
Trial end date:
2017-04-13
Target enrollment:
Participant gender:
Summary
This study is a two-part trial consisting of Part A (see NCT01628393) and Part B, presented
within this record.
The primary objective of Part B is to assess whether the clinical efficacy of ozanimod
(RPC1063) is superior to interferon beta-1a (IFN β-1a; Avonex®) in reducing the rate of
clinical relapses at the end of Month 24 in patients with relapsing multiple sclerosis (RMS).